相关实验视频
Updated: Jul 16, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.9K
减少老年人2型糖尿病过度治疗导致的低血糖症:HypoPrevent研究
Deborah A Koehn1, Kathleen Marie Dungan2, Amisha Wallia3
1VCU Stony Point Women's Health, Richmond, Virginia, USA.
Journal of the American Geriatrics Society
|September 22, 2023
概括
临床决策支持工具和共享决策通过降低治疗强度和改善日常生活影响,降低了2型糖尿病老年人的低血糖风险.
科学领域:
- 老年病的医生 老年病的医生
- 内分泌学 在内分泌学.
- 主要护理是指初级护理.
背景情况:
- 过度治疗导致的低血糖是患有2型糖尿病的老年人中显著而未被认可的问题.
- 糖尿病治疗强化很少被逆转,即使患者有低血糖的风险.
研究的目的:
- 评估临床决策支持 (CDS) 工具和共享决策 (SDM) 在降低低血糖风险方面的有效性.
- 评估这些干预措施对老年人非严重低血糖事件的影响.
主要方法:
- 一项前后单臂研究 (HypoPrevent) 涉及94名患有2型糖尿病的老年人,他们有低血糖的风险.
- 临床医生在6个月内使用CDS工具和SDM来设定个性化的HbA1c目标并调整低血糖药物.
- 患者报告的结果 (TRIM-HYPO) 评估了低血糖对日常活动的影响.
主要成果:
- 94%的患者设定了个性化的HbA1c目标,20%的患者使用胰岛素或硫尿素减少或消除.
- 患低血糖风险的人群减少了46% (p < 0.0001).
- 观察到低血糖对日常活动的影响显著减少.
结论:
- 一个CDS工具与SDM相结合,有效地减少了老年人患低血糖症的风险人口.
- 这些干预措施导致胰岛素和硫氨基酸的使用减少,生活质量得到改善.
- 这项研究强调了降低风险老年人群糖尿病治疗强度的好处.
相关概念视频
Diabetes: Management and Pharmacotherapy
302
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
302
Hypoglycemia and Glucagon
287
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
287
Insulin: Dosing Regimen and Adverse Effects
198
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
198
Oral Hypoglycemic Agents: Biguanides and Glitazones
223
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
223
Diabetes Mellitus: Type 2 and Gestational
2.5K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.5K
Diabetes Mellitus: Overview and Type I Subtype
2.7K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.7K

